loberamisal Archives - NeuroNews International

Positive loberamisal data underscore potential role for multi-target neuroprotective agents in...

6 February 2026

Stroke patients who intravenously received the novel neuroprotective medication loberamisal (NeuroDawn Pharmaceutical) on a daily basis—for 10 days and starting within 48 hours of...

Write to us
Editor: Jamie Bell [email protected]
Advertising: Abbie Richardson [email protected]

United Kingdom:

BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: [email protected]

United States:

BIBA Medical, North America
155 North Wacker Drive, Suite 4250, Chicago, IL 60606
TEL: +1 949 723 9309
Email: [email protected]

Terms and Conditions | Privacy Policy

Tag: loberamisal

Positive loberamisal data underscore potential role for multi-target neuroprotective agents in...